Publications by authors named "H Uludag"

Objectives: Breast cancer is the most common type of cancer among women and the second most common cause of death after lung cancer. The inhibitor of growth (ING) transcript levels are often suppressed in cancer cells, making it a promising candidate for cancer therapy. In this study, we aimed to formulate a polyplex that effectively carries and delivers pING4 to breast cancer cells.

View Article and Find Full Text PDF
Article Synopsis
  • Hematological disorders often lead to severe health issues, and traditional treatments can cause negative side effects without fixing the underlying problems.
  • Small interfering RNA (siRNA) molecules are emerging as a promising therapy because they can target and degrade specific mRNAs to stop harmful protein production in diseases like sickle cell anemia and various blood cancers.
  • There are challenges in effectively delivering siRNA to the right cells, leading to research focused on improved delivery methods, stability, and specificity to enhance treatment options for these conditions.
View Article and Find Full Text PDF

The therapeutic potential of small interfering RNAs (siRNAs) in gene-targeted treatments is substantial, but their suboptimal delivery impedes widespread clinical applications. Critical among these is the inability of siRNAs to traverse the cell membranes due to their anionic nature and high molecular weight. This limitation is particularly pronounced in lymphocytes, which pose additional barriers due to their smaller size and scant cytoplasm.

View Article and Find Full Text PDF

Approximately 25% of newly diagnosed AML patients display an internal tandem duplication (ITD) in the fms-like tyrosine kinase 3 (FLT3) gene. Although both multi-targeted and FLT3 specific tyrosine kinase inhibitors (TKIs) are being utilized for clinical therapy, drug resistance, short remission periods, and high relapse rates are challenges that still need to be tackled. RNA interference (RNAi), mediated by short interfering RNA (siRNA), presents a mechanistically distinct therapeutic platform with the potential of personalization due to its gene sequence-driven mechanism of action.

View Article and Find Full Text PDF

The piggyBac transposon/transposase system has been explored for long-term, stable gene expression to execute genomic integration of therapeutic genes, thus emerging as a strong alternative to viral transduction. Most studies with piggyBac transposition have employed physical methods for successful delivery of the necessary components of the piggyBac system into the cells. Very few studies have explored polymeric gene delivery systems.

View Article and Find Full Text PDF